<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03530683</url>
  </required_header>
  <id_info>
    <org_study_id>TTI-622-01</org_study_id>
    <nct_id>NCT03530683</nct_id>
  </id_info>
  <brief_title>A Trial of TTI-622 in Patients With Advanced Hematologic Malignancies</brief_title>
  <acronym>TTI-622-01</acronym>
  <official_title>A Phase 1a/1b Dose-Escalation and Expansion Trial of TTI-622 in Patients With Advanced Hematologic Malignancies, Including Lymphoma, Leukemia, and Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trillium Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Trillium Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, open-label, phase 1a/1b Dose Escalation and Expansion Trial of TTI-622 in&#xD;
      subjects with Advanced Hematologic Malignancies, Including Lymphoma, Leukemia, and Multiple&#xD;
      Myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a trial of TTI-622 in subjects with relapsed or refractory lymphoma or multiple&#xD;
      myeloma (MM) and subjects with newly diagnosed acute myeloid leukemia (AML).&#xD;
&#xD;
      This trial will be conducted in 2 phases: Phase 1a (Dose-Escalation Phase for Single-Agent&#xD;
      TTI-622) and Phase 1b (TTI-622 Combinations).&#xD;
&#xD;
      In the Dose-Escalation Phase for Single-Agent TTI-622, subjects with relapsed or refractory&#xD;
      lymphoma will be enrolled in sequential dose cohorts.&#xD;
&#xD;
      In the Combination Treatment part, subjects will be included in 1 of 3 cohorts: (1) subjects&#xD;
      with newly diagnosed TP53-mutated AML will be treated with TTI-622 + azacitidine; (2) elderly&#xD;
      subjects (≥75 years old) or subjects unfit for intensive induction chemotherapies with newly&#xD;
      diagnosed TP53-wildtype AML will be treated with TTI-622 + azacitidine and venetoclax; and&#xD;
      (3) subjects with relapsed or refractory MM will be treated with TTI-622 + carfilzomib and&#xD;
      dexamethasone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1a: Frequency and severity of adverse events (AEs)</measure>
    <time_frame>Through study completion, up to 18 months</time_frame>
    <description>To characterize the safety profile (incidence of AEs) and dose-limiting toxicities (DLTs) of TTI-622.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1b: Frequency and severity of AEs</measure>
    <time_frame>Through study completion, up to 18 months</time_frame>
    <description>To characterize the safety profile (incidence of AEs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1b: Efficacy of each combination treatment</measure>
    <time_frame>Through study completion, up to 18 months</time_frame>
    <description>To evaluate preliminary efficacy (response rate) of each combination treatment in the 3 Cohorts (A to C).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Characterize the TTI-622 pharmacokinetics (PK) parameter t1/2</measure>
    <time_frame>Through study completion, up to 18 months</time_frame>
    <description>To characterize t1/2 of TTI-622.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Characterize the TTI-622 PK parameter AUC0-t</measure>
    <time_frame>Through study completion, up to 18 months</time_frame>
    <description>To characterize AUC0-t of TTI-622.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Characterize the TTI-622 PK parameter AUC0-tau</measure>
    <time_frame>Through study completion, up to 18 months</time_frame>
    <description>To characterize AUC0-tau of TTI-622.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Characterize the TTI-622 PK parameter AUC0-infinity</measure>
    <time_frame>Through study completion, up to 18 months</time_frame>
    <description>To characterize AUC0-infinity of TTI-622.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Characterize the TTI-622 PK parameter Tmax</measure>
    <time_frame>Through study completion, up to 18 months</time_frame>
    <description>To characterize Tmax of TTI-622.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Characterize the TTI-622 PK parameter Cmax</measure>
    <time_frame>Through study completion, up to 18 months</time_frame>
    <description>To characterize Cmax of TTI-622.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Characterize the TTI-622 PK parameter Cmin</measure>
    <time_frame>Through study completion, up to 18 months</time_frame>
    <description>To characterize Cmin of TTI-622.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Characterize the TTI-622 PK parameter Cavg</measure>
    <time_frame>Through study completion, up to 18 months</time_frame>
    <description>To characterize Cavg of TTI-622.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Characterize the clearance of TTI-622</measure>
    <time_frame>Through study completion, up to 18 months</time_frame>
    <description>To characterize clearance of TTI-622.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Characterize the volume of distribution of TTI-622</measure>
    <time_frame>Through study completion, up to 18 months</time_frame>
    <description>To characterize volume of distribution of TTI-622.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Characterize the immunogenicity of TTI-622</measure>
    <time_frame>Through study completion, up to 18 months</time_frame>
    <description>To characterize the incidence of anti-drug antibodies (ADA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Characterize the preliminary evidence of antitumor activity of TTI-622: overall response rate</measure>
    <time_frame>Through study completion, up to 18 months</time_frame>
    <description>To determine the overall response rate (ORR) for participants treated with TTI-622.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Characterize the preliminary evidence of antitumor activity of TTI-622: disease control rate</measure>
    <time_frame>Through study completion, up to 18 months</time_frame>
    <description>To determine the disease control rate (DCR) for participants treated with TTI-622.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Characterize the preliminary evidence of antitumor activity of TTI-622: time to response</measure>
    <time_frame>Through study completion, up to 18 months</time_frame>
    <description>To determine the time to response (TTR) for participants treated with TTI-622.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Characterize the preliminary evidence of antitumor activity of TTI-622: duration of response</measure>
    <time_frame>Through study completion, up to 18 months</time_frame>
    <description>To determine the duration of response (DOR) for participants treated with TTI-622.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Characterize the preliminary evidence of antitumor activity of TTI-622: progression free survival</measure>
    <time_frame>Through study completion, up to 18 months</time_frame>
    <description>To determine the progression free survival (PFS) time for participants treated with TTI-622.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Characterize the TTI-622 PK parameter t1/2 when combined with selected anticancer treatments</measure>
    <time_frame>Through study completion, up to 18 months</time_frame>
    <description>To characterize t1/2 of TTI-622 when combined with selected anticancer treatments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Characterize the TTI-622 PK parameter AUC0-t when combined with selected anticancer treatments</measure>
    <time_frame>Through study completion, up to 18 months</time_frame>
    <description>To characterize AUC0-t of TTI-622 when combined with selected anticancer treatments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Characterize the TTI-622 PK parameter AUC0-tau when combined with selected anticancer treatments</measure>
    <time_frame>Through study completion, up to 18 months</time_frame>
    <description>To characterize AUC0-tau of TTI-622 when combined with selected anticancer treatments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Characterize the TTI-622 PK parameter AUC0-infinity when combined with selected anticancer treatments</measure>
    <time_frame>Through study completion, up to 18 months</time_frame>
    <description>To characterize AUC0-infinity of TTI-622 when combined with selected anticancer treatments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Characterize the TTI-622 PK parameter Tmax when combined with selected anticancer treatments</measure>
    <time_frame>Through study completion, up to 18 months</time_frame>
    <description>To characterize Tmax of TTI-622 when combined with selected anticancer treatments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Characterize the TTI-622 PK parameter Cmax when combined with selected anticancer treatments</measure>
    <time_frame>Through study completion, up to 18 months</time_frame>
    <description>To characterize Cmax of TTI-622 when combined with selected anticancer treatments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Characterize the TTI-622 PK parameter Cmin when combined with selected anticancer treatments</measure>
    <time_frame>Through study completion, up to 18 months</time_frame>
    <description>To characterize Cmin of TTI-622 when combined with selected anticancer treatments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Characterize the TTI-622 PK parameter Cavg when combined with selected anticancer treatments</measure>
    <time_frame>Through study completion, up to 18 months</time_frame>
    <description>To characterize Cavg of TTI-622 when combined with selected anticancer treatments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Characterize the clearance of TTI-622 when combined with selected anticancer treatments</measure>
    <time_frame>Through study completion, up to 18 months</time_frame>
    <description>To characterize clearance of TTI-622 when combined with selected anticancer treatments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Characterize the volume of distribution of TTI-622 when combined with selected anticancer treatments</measure>
    <time_frame>Through study completion, up to 18 months</time_frame>
    <description>To characterize volume of distribution of TTI-622 when combined with selected anticancer treatments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Characterize the immunogenicity of TTI-622 when combined with selected anticancer treatments</measure>
    <time_frame>Through study completion, up to 18 months</time_frame>
    <description>To characterize the incidence of anti-drug antibodies (ADA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Characterize the preliminary evidence of antitumour activity of TTI-622 when combined with selected anticancer treatments: disease control rate</measure>
    <time_frame>Through study completion, up to 18 months</time_frame>
    <description>To determine the disease control rate (DCR) for participants treated with TTI-622 when combined with selected anticancer treatments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Characterize the preliminary evidence of antitumour activity of TTI-622 when combined with selected anticancer treatments: time to response</measure>
    <time_frame>Through study completion, up to 18 months</time_frame>
    <description>To determine the time to response (TTR) for participants treated with TTI-622 when combined with selected anticancer treatments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Characterize the preliminary evidence of antitumour activity of TTI-622 when combined with selected anticancer treatments: event-free survival</measure>
    <time_frame>Through study completion, up to 18 months</time_frame>
    <description>To determine event-free survival (EFS; for Cohorts A and B) time for participants treated with TTI-622 when combined with selected anticancer treatments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Characterize the preliminary evidence of antitumour activity of TTI-622 when combined with selected anticancer treatments: duration of response</measure>
    <time_frame>Through study completion, up to 18 months</time_frame>
    <description>To determine the duration of response (DOR) for participants treated with TTI-622 when combined with selected anticancer treatments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Characterize the preliminary evidence of antitumour activity of TTI-622 when combined with selected anticancer treatments: progression-free survival</measure>
    <time_frame>Through study completion, up to 18 months</time_frame>
    <description>To determine the progression-free survival (PFS) time for participants treated with TTI-622 when combined with selected anticancer treatments.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>TTI-622 Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A: TTI-622 + Azacitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B: TTI-622 + Azacitidine and Venetoclax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C: TTI-622 + Carfilzomib and Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TTI-622</intervention_name>
    <description>TTI-622 will be administered by intravenous infusion.</description>
    <arm_group_label>Cohort A: TTI-622 + Azacitidine</arm_group_label>
    <arm_group_label>Cohort B: TTI-622 + Azacitidine and Venetoclax</arm_group_label>
    <arm_group_label>Cohort C: TTI-622 + Carfilzomib and Dexamethasone</arm_group_label>
    <arm_group_label>TTI-622 Monotherapy</arm_group_label>
    <other_name>SIRPα-IgG4 Fc</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>75 mg/m^2 intravenous (IV) or subcutaneous (SC) daily for 7 days, repeated every 4 weeks</description>
    <arm_group_label>Cohort A: TTI-622 + Azacitidine</arm_group_label>
    <arm_group_label>Cohort B: TTI-622 + Azacitidine and Venetoclax</arm_group_label>
    <other_name>VIDAZA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>400 mg orally daily for each day of each cycle (except for Cycle 1, where Day 1=100 mg and Day 2=200 mg; first 7 doses taken in clinic). The ramp-up and target dose of venetoclax will be adjusted per the package insert in subjects who are taking concomitant moderate or strong CYP3A4 inhibitors or posaconazole</description>
    <arm_group_label>Cohort B: TTI-622 + Azacitidine and Venetoclax</arm_group_label>
    <other_name>VENCLEXTA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <description>Days 1, 8, and 15 of 28-day cycles; 20 mg/m^2 IV given on Cycle (C) 1 Day (D) 1, and if tolerated, then 70 mg/m^2 IV given starting on C1D8 and subsequent doses thereafter</description>
    <arm_group_label>Cohort C: TTI-622 + Carfilzomib and Dexamethasone</arm_group_label>
    <other_name>KYPROLIS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>40 mg orally or IV on Days 1, 8, 15, and 22 of 28-day cycles</description>
    <arm_group_label>Cohort C: TTI-622 + Carfilzomib and Dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria (Phase 1a and Phase 1b, all Cohorts):&#xD;
&#xD;
          1. Available fresh or archived tumor tissue.&#xD;
&#xD;
          2. Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2.&#xD;
&#xD;
          3. Adequate coagulation function.&#xD;
&#xD;
          4. Adequate hepatic function.&#xD;
&#xD;
          5. Adequate hematologic status.&#xD;
&#xD;
          6. Adequate renal function.&#xD;
&#xD;
          7. Recovery from non-hematopoietic toxicities of previous anticancer drugs or&#xD;
             radiotherapy or previous surgeries to ≤Grade 1 (or to baseline grade if condition was&#xD;
             pre-existing).&#xD;
&#xD;
        Key Inclusion Criteria (Phase 1a): Histologically confirmed relapsed/refractory lymphoma&#xD;
        (Hodgkin or non-Hodgkin).&#xD;
&#xD;
        Key Inclusion Criteria (Phase 1b Cohort A): Histologically confirmed, newly diagnosed&#xD;
        TP53-mutated Acute Myeloid Leukemia (AML).&#xD;
&#xD;
        Key Inclusion Criteria (Phase 1b Cohort B): Histologically confirmed, newly diagnosed&#xD;
        TP53-wildtype AML, elderly or unfit for more aggressive treatment.&#xD;
&#xD;
        Inclusion Criteria (Phase 1b Cohort C): Histologically documented relapsed/refractory&#xD;
        Multiple Myeloma (MM).&#xD;
&#xD;
        Key Exclusion Criteria (Phase 1a and Phase 1b, all Cohorts):&#xD;
&#xD;
          1. Known, current central nervous system disease involvement.&#xD;
&#xD;
          2. Use of any investigational agent or any anticancer drug within 14 days before planned&#xD;
             start of study treatment (within 4 weeks for antibody-based therapies and within 8&#xD;
             weeks for cell-based therapies).&#xD;
&#xD;
          3. Subjects who have undergone radiation therapy within 14 days of study treatment&#xD;
             administration.&#xD;
&#xD;
          4. Hematopoietic stem cell transplant within 90 days before the planned start of study&#xD;
             treatment or subjects with active graft-vs-host disease, with the exception of Grade 1&#xD;
             skin involvement.&#xD;
&#xD;
          5. Major surgery within 30 days before planned start of study treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ingmar Bruns, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Trillium Therapeutics Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathleen Large, RN, MSN</last_name>
    <phone>875-412-7029</phone>
    <phone_ext>211</phone_ext>
    <email>kathleen2@trilliumtherapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Naomi Molloy</last_name>
    <email>naomi@trilliumtherapeutics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute at Colorado Blood Cancer Institute (CBCI)</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ben Burtness</last_name>
      <phone>720-754-8064</phone>
      <email>ben.burtness@sarahcannon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Georgetown Lombardi Comprehensive Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melin Vranesic</last_name>
      <phone>202-687-0160</phone>
      <email>mv764@georgetown.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lakes Research</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erica Chapman</last_name>
      <phone>734-232-0716</phone>
      <email>echapman@med.umich.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megi Gojka</last_name>
      <phone>313-576-9685</phone>
      <email>gojkam@karmanos.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tala Shekarkhand</last_name>
      <phone>646-608-3915</phone>
      <email>shekarkt@mskcc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center Research, LLC</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>University of TN Medical Center/Cancer Institute</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krissy Bollig, RN, BSN</last_name>
      <phone>865-305-7469</phone>
      <email>klbollig@utmck.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Peyton, RN, BSN, OCN</last_name>
      <phone>713-745-8923</phone>
      <email>kfpeyton@mdanderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute - Research</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krystle Pagarigan</last_name>
      <phone>206-386-2098</phone>
      <email>krystle.pagarigan@swedish.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 8, 2018</study_first_submitted>
  <study_first_submitted_qc>May 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2018</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoplasms</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Myeloma</keyword>
  <keyword>Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

